Evicenter
MarkdownMedical informationP&T meetings
Adrabetadex (Lembaz)

Infantile-onset Niemann-Pick disease type C

Also known as VTS-270
Last updated
196 sources

Product information and disease descriptionProduct description

Phase of product development

31 evidence topics · 26 sources

Summary: regulatory status and development history
  • Approval: the FDA approved Lembaz (adrabetadex) injection under NDA 220996 on November 17, 2026, as a “Type 1 - New Molecular Entity” with priority review and orphan status. The FDA describes it as the first treatment shown to help people with a “severe form of Niemann-Pick disease type C (NPC) live longer”. Beren Therapeutics states that LEMBAZ will be available at commercial treatment sites nationwide in early December.
  • Application and review: Beren Therapeutics, through its subsidiary Mandos LLC, submitted the NDA on December 17, 2025 for the treatment of patients with infantile-onset NPC. The application was based on an externally controlled survival analysis, biomarker and nonclinical confirmatory evidence, and patient experience narratives. The FDA granted priority review and assigned a PDUFA target action date of August 17, 2026. Beren's March 18, 2026 response to an FDA information request was classified as a major amendment, which extended the goal date by three months to November 17, 2026. The application was not referred to an FDA advisory committee.
  • Designations: the FDA designated 2-hydroxypropyl-B-cyclodextrin an orphan drug for the treatment of Niemann Pick disease, type C on 02/18/2013, with Mandos LLC as the sponsor. The European Commission granted orphan designation EU/3/13/1124 on 26 April 2013 to the International Niemann-Pick Disease Alliance; sponsorship was transferred to Vtesse Europe Limited in February 2015, Mallinckrodt Pharmaceuticals Ireland Limited in September 2018, Rapport Global Strategic Services Ireland Limited in December 2021, and Eliquent Life Sciences Limited in August 2024. Adrabetadex also holds rare pediatric disease designation. The FDA granted Vtesse Breakthrough Therapy designation for VTS-270 in Niemann-Pick Type C1 disease on January 6, 2016 and later rescinded it based on data from a 12-month phase 2b/3 trial; a second Breakthrough Therapy designation, for infantile-onset NPC, was announced on December 9, 2025 and was informed by an externally controlled survival analysis.
  • Priority review voucher and patents: the FDA granted a rare pediatric disease priority review voucher (PRV NDA 220996) with the approval, which may be transferred, including by sale. Earlier agreements refer to shares of voucher proceeds: Sucampo agreed in 2017 to pay Vtesse shareholders a share of net proceeds from monetization of the voucher, and the Mallinckrodt plan of reorganization refers to the Debtors' 63% retained ownership interest in the voucher. Beren states that its intellectual property estate provides patent protection through 2046, excluding potential patent term extensions, patent term adjustments, and supplementary protection certificates, and that it holds more than 30 issued U.S. patents.
  • Development history: researchers at the NIH National Center for Advancing Translational Sciences and the Eunice Kennedy Shriver National Institute of Child Health and Human Development, in collaboration with Vtesse, developed VTS-270. After its launch in January 2015, Vtesse fully enrolled the registrational study at 20 clinical trial sites. Sucampo acquired Vtesse on April 3, 2017 for upfront consideration of $200 million plus contingent royalties, and Mallinckrodt acquired Sucampo, and with it VTS-270, in February 2018. At a Type A meeting in August 2018, the FDA indicated that approvability would be based on the totality of data; in November 2018 Mallinckrodt announced that the registration trial did not show a statistically significant separation from placebo. In the three months ended December 27, 2019, Mallinckrodt recognized a full impairment of $274.5 million on the VTS-270 asset, “primarily driven by continued regulatory challenges”, and trial NCT03643562 ended after the sponsor determined that the benefit-risk profile of adrabetadex was not favorable. Mandos acquired the program from Mallinckrodt in 2021, held an introductory call and a Type C meeting with the FDA, and completed new analyses of adrabetadex before the NDA submission.
  • Earlier timelines: in April 2017 Sucampo expected pivotal trial results in mid-2018 and a launch beginning in 2019, and a YODA Project data request projected an NDA submission by December 2023 toward accelerated approval.
Orphan drug designation in the United States, February 2013